In breast cancer, IL-6 pre-treatment followed by SIRT1 activation by SRT1720 combined with dual PI3K/mTOR inhibitor NVP-BEZ235 obviously increased sensitivity of the cancer stem cells to radiation, so that late stage breast cancer cells therapeutic effect was effectively improved (Fatehi et al., 2018; Masoumi et al., 2020). This evidence concerns the gene PIK3CA and breast carcinoma.